Pharmacological strategies to prevent contrast-induced acute kidney injury

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Pattharanitima, Pattharawin ^a   Tasanarong, Adis ^a  

^a THAMMASAT UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANTIOXIDANT; ASCORBIC ACID; ATRIAL NATRIURETIC FACTOR; BICARBONATE; CONTRAST MEDIUM; CREATININE; DOPAMINE; FENOLDOPAM; FUROSEMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOTONIC SOLUTION; INFUSION FLUID; ISOTONIC SOLUTION; MANNITOL; NEBIVOLOL; OXYGEN RADICAL; PLACEBO; PROSTAGLANDIN; SODIUM CHLORIDE; THEOPHYLLINE; TOCOPHEROL; VASODILATOR AGENT; FREE RADICAL;

ACUTE CORONARY SYNDROME; ANGIOCARDIOGRAPHY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BODY WEIGHT; CONTRAST INDUCED NEPHROPATHY; DRUG EFFICACY; GLOMERULUS FILTRATION RATE; HUMAN; INTRAVENOUS ADMINISTRATION; KIDNEY PLASMA FLOW; MEDICATION THERAPY MANAGEMENT; META ANALYSIS; NONHUMAN; OXIDATIVE STRESS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SYSTEMATIC REVIEW; VASOCONSTRICTION; ACUTE KIDNEY INJURY; CHEMICALLY INDUCED; DRUG EFFECTS; FEMALE; KIDNEY; MALE; PATHOLOGY; TOXICITY;

ACUTE KIDNEY INJURY; CONTRAST MEDIA; CORONARY ANGIOGRAPHY; FEMALE; FREE RADICALS; HUMANS; KIDNEY; MALE; RISK FACTORS; VASOCONSTRICTION;

EID: 84897834199     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/236930     Document Type: Article

References (135)

1. Berns A. S., Nephrotoxicity of contrast media. Kidney International 1989 36 4 730 740 2-s2.0-0024429334 (Pubitemid 19239569)
2. Rudnick M. R., Goldfarb S., Tumlin J., Contrast-induced nephropathy: is the picture any clearer? Clinical Journal of the American Society of Nephrology 2008 3 1 261 262 2-s2.0-38749125921 10.2215/CJN.04951107
3. ACT Investigators, Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized acetylcysteine for contrast-induced nephropathy trial (ACT). Circulation 2011 124 11 1250 1259 2-s2.0-80052770288 10.1161/CIRCULATIONAHA. 111.038943
4. Gurm H. S., Smith D. E., Berwanger O., Share D., Schreiber T., Moscucci M., Nallamothu B. K., Contemporary use and effectiveness of N-acetylcysteine in preventing contrast-induced nephropathy among patients undergoing percutaneous coronary intervention. Journal of the American College of Cardiology 2012 5 1 98 104 2-s2.0-84855589639 10.1016/j.jcin.2011.09.019
5. Tepel M., Aspelin P., Lameire N., Contrast-induced nephropathy: a clinical and evidence-based approach. Circulation 2006 113 14 1799 1806 2-s2.0-33646683337 10.1161/CIRCULATIONAHA.105.595090 (Pubitemid 43958473)
6. Goldenberg I., Matetzky S., Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies. CMAJ 2005 172 11 1461 1471 2-s2.0-20444410007 10.1503/cmaj.1040847 (Pubitemid 40803495)
7. Fishbane S., Durham J. H., Marzo K., Rudnick M., N-acetylcysteine in the prevention of radiocontrast-induced nephropathy. Journal of the American Society of Nephrology 2004 15 2 251 260 2-s2.0-0942287101 10.1097/01.ASN.0000107562. 68920.92 (Pubitemid 38140765)
8. Gleeson T. G., Bulugahapitiya S., Contrast-induced nephropathy. The American Journal of Roentgenology 2004 183 6 1673 1689 2-s2.0-16644390328 (Pubitemid 44210538)
9. Maeder M., Klein M., Fehr T., Rickli H., Contrast nephropathy: review focusing on prevention. Journal of the American College of Cardiology 2004 44 9 1763 1771 2-s2.0-7044245840 10.1016/j.jacc.2004.06.075 (Pubitemid 39424073)
10. Murphy S. W., Barrett B. J., Parfrey P. S., Contrast nephropathy. Journal of the American Society of Nephrology 2000 11 1 177 182 2-s2.0-0033982499 (Pubitemid 30020439)
11. Thomsen H. S., Morcos S. K., Contrast media and the kidney: European Society of Urogenital Radiology (ESUR) guidelines. British Journal of Radiology 2003 76 908 513 518 2-s2.0-0041932452 10.1259/bjr/26964464 (Pubitemid 37028403)
12. Gami A. S., Garovic V. D., Contrast nephropathy after coronary angiography. Mayo Clinic Proceedings 2004 79 2 211 219 2-s2.0-0942276279 (Pubitemid 38140805)
13. Rudnick M. R., Goldfarb S., Wexler L., Ludbrook P. A., Murphy M. J., Halpern E. F., Hill J. A., Winniford M., Cohen M. B., VanFossen D. B., Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol cooperative study. Kidney International 1995 47 1 254 261 2-s2.0-0028936849
14. Kurnik B. R. C., Weisberg L. S., Cuttler I. M., Kurnik P. B., Effects of atrial natriuretic peptide versus mannitol on renal blood flow during radiocontrast infusion in chronic renal failure. Journal of Laboratory and Clinical Medicine 1990 116 1 27 35 2-s2.0-0025102461 (Pubitemid 20250744)
15. Bonvalet J.-P., Pradelles P., Farman N., Segmental synthesis and actions of prostaglandins along the nephron. The American Journal of Physiology-Renal Fluid and Electrolyte Physiology 1987 253 3, part 2 F377 F387 2-s2.0-0023574533
16. Agmon Y., Peleg H., Greenfeld Z., Rosen S., Brezis M., Nitric oxide and prostanoids protect the renal outer medulla from radiocontrast toxicity in the rat. Journal of Clinical Investigation 1994 94 3 1069 1075 2-s2.0-0027932817 (Pubitemid 24286448)
17. Freeman R. V., O'Donnell M., Share D., Meengs W. L., Kline-Rogers E., Clark V. L., DeFranco A. C., Eagle K. A., McGinnity J. G., Patel K., Maxwell-Eward A., Bondie D., Moscucci M., Nephropathy requiring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose. The American Journal of Cardiology 2002 90 10 1068 1073 2-s2.0-0037112120 10.1016/S0002-9149(02)02771-6 (Pubitemid 35335595)
18. Nikolsky E., Mehran R., Turcot D., Aymong E. D., Mintz G. S., Lasic Z., Lansky A. J., Tsounias E., Moses J. W., Stone G. W., Leon M. B., Dangas G. D., Impact of chronic kidney disease on prognosis of patients with diabetes mellitus treated with percutaneous coronary intervention. The American Journal of Cardiology 2004 94 3 300 305 2-s2.0-3242668206 10.1016/j.amjcard.2004.04.023 (Pubitemid 38962693)
19. Gruberg L., Mintz G. S., Mehran R., Dangas G., Lansky A. J., Kent K. M., Pichard A. D., Satler L. F., Leon M. B., The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. Journal of the American College of Cardiology 2000 36 5 1542 1548 2-s2.0-0034332861 10.1016/S0735-1097(00)00917-7
20. Persson P. B., Hansell P., Liss P., Pathophysiology of contrast medium-induced nephropathy. Kidney International 2005 68 1 14 22 2-s2.0-24944514021 10.1111/j.1523-1755.2005.00377.x (Pubitemid 43181360)
21. Brezis M., Rosen S., Mechanisms of disease: hypoxia of the renal medulla-its implications for disease. The New England Journal of Medicine 1995 332 10 647 655 2-s2.0-0029640011 10.1056/NEJM199503093321006
22. Tumlin J., Stacul F., Adam A., Becker C. R., Davidson C., Lameire N., McCullough P. A., Pathophysiology of contrast-induced nephropathy. The American Journal of Cardiology 2006 98 6, supplement 1 14 20 2-s2.0-33747888493 10.1016/j.amjcard.2006.01.020 (Pubitemid 44292090)
23. Romano G., Briguori C., Quintavalle C., Zanca C., Rivera N. V., Colombo A., Condorelli G., Contrast agents and renal cell apoptosis. European Heart Journal 2008 29 20 2569 2576 2-s2.0-54149089710 10.1093/eurheartj/ehn197
24. Weisbord S. D., Palevsky P. M., Prevention of contrast-induced nephropathy with volume expansion. Clinical Journal of the American Society of Nephrology 2008 3 1 273 280 2-s2.0-38749129181 10.2215/CJN.02580607
25. Mueller C., Buerkle G., Buettner H. J., Petersen J., Perruchoud A. P., Eriksson U., Marsch S., Roskamm H., Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Archives of Internal Medicine 2002 162 3 329 336 2-s2.0-0037059951 (Pubitemid 34127411)
26. Aspelin P., Aubry P., Fransson S.-G., Strasser R., Willenbrock R., Berg K. J., Nephrotoxic effects in high-risk patients undergoing angiography. The New England Journal of Medicine 2003 348 6 491 499 2-s2.0-0037421597 10.1056/NEJMoa021833 (Pubitemid 36159884)
27. Larson T. S., Hudson K., Mertz J. I., Renal vasoconstrictive response to contrast medium. The role of sodium balance and the renin-angiotensin system. Journal of Laboratory and Clinical Medicine 1983 101 3 385 391 2-s2.0-0020696423 (Pubitemid 13164264)
28. Yoshioka T., Fogo A., Beckman J. K., Reduced activity of antioxidant enzymes underlies contrast media-induced renal injury in volume depletion. Kidney International 1992 41 4 1008 1015 2-s2.0-0026562173
29. Erley C. M., Heyne N., Rossmeier S., Vogel T., Risler T., Osswald H., Adenosine and extracellular volume in radiocontrast media-induced nephropathy. Kidney International, Supplement 1998 54 67 S192 S194 2-s2.0-0031720937 (Pubitemid 28405714)
30. Solomon R., Werner C., Mann D., D'Elia J., Silva P., Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents. The New England Journal of Medicine 1994 331 21 1416 1420 2-s2.0-0028033015 10.1056/NEJM199411243312104 (Pubitemid 24348355)
31. Taylor A. J., Hotchkiss D., Morse R. W., McCabe J., PREPARED: preparation for angiography in renal dysfunction: a randomized trial of inpatient vs outpatient hydration protocols for cardiac catheterization in mild-to-moderate renal dysfunction. Chest 1998 114 6 1570 1574 2-s2.0-0032252772 (Pubitemid 128487477)
32. Trivedi H. S., Moore H., Nasr S., Aggarwal K., Agrawal A., Goel P., Hewett J., A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity. Nephron. Clinical practice 2003 93 1 C29 C34 2-s2.0-0042496326
33. Dussol B., Morange S., Loundoun A., Auquier P., Berland Y., A randomized trial of saline hydration to prevent contrast nephropathy in chronic renal failure patients. Nephrology Dialysis Transplantation 2006 21 8 2120 2126 2-s2.0-33748076434 10.1093/ndt/gfl133 (Pubitemid 44295036)
34. Cho R., Javed N., Traub D., Kodali S., Atem F., Srinivasan V., Oral hydration and alkalinization is noninferior to intravenous therapy for prevention of contrast-induced nephropathy in patients with chronic kidney disease. Journal of Interventional Cardiology 2010 23 5 460 466 2-s2.0-77957744103 10.1111/j.1540-8183.2010.00585.x
35. Merten G. J., Burgess W. P., Gray L. V., Holleman J. H., Roush T. S., Kowalchuk G. J., Bersin R. M., Van Moore A., Simonton C. A. III, Rittase R. A., Norton H. J., Kennedy T. P., Prevention of contrast-induced nephropathy with sodium bicarbonate: A randomized controlled trial. Journal of the American Medical Association 2004 291 19 2328 2334 2-s2.0-2442590642 10.1001/jama.291.19. 2328 (Pubitemid 38656299)
36. Recio-Mayoral A., Chaparro M., Prado B., Cózar R., Méndez I., Banerjee D., Kaski J. C., Cubero J., Cruz J. M., The reno-protective effect of hydration with sodium bicarbonate plus N-acetylcysteine in patients undergoing emergency percutaneous coronary intervention. The RENO study. Journal of the American College of Cardiology 2007 49 12 1283 1288 2-s2.0-33947512067 10.1016/j.jacc.2006.11.034 (Pubitemid 46467227)
37. Jang J. S., Jin H. Y., Seo J. S., Yang T. H., Kim D. K., Kim T. H., Urm S. H., Kim D. S., Seol S. H., Kim D. I., Cho K. I., Kim B. H., Park Y. H., Je H. G., Ahn J. M., Kim W. J., Lee J. Y., Lee S. W., Sodium bicarbonate therapy for the prevention of contrast-induced acute kidney injury-a systematic review and meta-analysis. Circulation Journal 2012 76 9 2255 2265
38. Hogan S. E., L'Allier P., Chetcuti S., Grossman P. M., Nallamothu B. K., Duvernoy C., Bates E., Moscucci M., Gurm H. S., Current role of sodium bicarbonate-based preprocedural hydration for the prevention of contrast-induced acute kidney injury: a meta-analysis. The American Heart Journal 2008 156 3 414 421 2-s2.0-49949098247 10.1016/j.ahj.2008.05.014
39. Kanbay M., Covic A., Coca S. G., Turgut F., Akcay A., Parikh C. R., Sodium bicarbonate for the prevention of contrast-induced nephropathy: a meta-analysis of 17 randomized trials. International Urology and Nephrology 2009 41 3 617 627 2-s2.0-67649946111 10.1007/s11255-009-9569-2
40. Navaneethan S. D., Singh S., Appasamy S., Wing R. E., Sehgal A. R., Sodium bicarbonate therapy for prevention of contrast-induced nephropathy: a systematic review and meta-analysis. The American Journal of Kidney Diseases 2009 53 4 617 627 2-s2.0-62749137422 10.1053/j.ajkd.2008.08.033
41. Zoungas S., Ninomiya T., Huxley R., Cass A., Jardine M., Gallagher M., Patel A., Vasheghani-Farahani A., Sadigh G., Perkovic V., Systematic review: sodium bicarbonate treatment regimens for the prevention of contrast-induced nephropathy. Annals of Internal Medicine 2009 151 9 631 638 2-s2.0-70450220298 10.1059/0003-4819-151-9-200911030-00008
42. Kunadian V., Zaman A., Spyridopoulos I., Qiu W., Sodium bicarbonate for the prevention of contrast induced nephropathy: a meta-analysis of published clinical trials. European Journal of Radiology 2011 79 1 48 55 2-s2.0-78049390634 10.1016/j.ejrad.2009.12.015
43. Cotgreave I., Moldeus P., Schuppe I., The metabolism of N-acetylcysteine by human endothelial cells. Biochemical Pharmacology 1991 42 1 13 16 2-s2.0-0025875051 10.1016/0006-2952(91)90674-T
44. Parvez Z., Rahman M. A., Moncada R., Contrast media-induced lipid peroxidation in the rat kidney. Investigative Radiology 1989 24 9 697 702 2-s2.0-0024470728 (Pubitemid 19233503)
45. Bakris G. L., Lass N., Gaber A. O., Jones J. D., Burnett J. C. Jr., Radiocontrast medium-induced declines in renal function: a role for oxygen free radicals. The American Journal of Physiology-Renal Fluid and Electrolyte Physiology 1990 258 1 F115 F120 2-s2.0-0025019379 (Pubitemid 20063077)
46. Baliga R., Ueda N., Walker P. D., Shah S. V., Oxidant mechanisms in toxic acute renal failure. The American Journal of Kidney Diseases 1997 29 3 465 477 2-s2.0-0031055848 (Pubitemid 27106573)
47. Tepel M., van der Giet M., Schwarzfeld C., Laufer U., Liermann D., Zidek W., Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. The New England Journal of Medicine 2000 343 3 180 184 2-s2.0-0034691822 10.1056/NEJM200007203430304 (Pubitemid 30489215)
48. Shyu K.-G., Cheng J.-J., Kuan P., Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. Journal of the American College of Cardiology 2002 40 8 1383 1388 2-s2.0-0037120963 10.1016/S0735-1097(02)02308-2 (Pubitemid 35192860)
49. Kay J., Chow W. H., Chan T. M., Lo S. K., Kwok O. H., Yip A., Fan K., Lee C. H., Lam W. F., Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. Journal of the American Medical Association 2003 289 5 553 558 2-s2.0-0037419923 10.1001/jama.289.5.553 (Pubitemid 37428626)
50. Webb J. G., Pate G. E., Humphries K. H., Buller C. E., Shalansky S., Al Shamari A., Sutander A., Williams T., Fox R. S., Levin A., A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect. The American Heart Journal 2004 148 3 422 429 2-s2.0-4644237693 10.1016/j.ahj.2004. 03.041 (Pubitemid 39265114)
51. Birck R., Krzossok S., Markowetz F., Schnülle P., van der Woude F. J., Braun C., Acetylcysteine for prevention of contrast nephropathy: meta-analysis. The Lancet 2003 362 9384 598 603 2-s2.0-0042466568 10.1016/S0140-6736(03)14189-X (Pubitemid 37013299)
52. Isenbarger D. W., Kent S. M., O'Malley P. G., Meta-analysis of randomized clinical trials on the usefulness of acetylcysteine for prevention of contrast nephropathy. The American Journal of Cardiology 2003 92 12 1454 1458 2-s2.0-0347627632 10.1016/j.amjcard.2003.08.059 (Pubitemid 37532572)
53. Alonso A., Lau J., Jaber B. L., Weintraub A., Sarnak M. J., Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease: a meta-analysis of randomized, controlled trials. The American Journal of Kidney Diseases 2004 43 1 1 9 2-s2.0-0347990333 10.1053/j.ajkd.2003.09.009 (Pubitemid 38049429)
54. Bagshaw S. M., Ghali W. A., Acetylcysteine for prevention of contrast-induced nephropathy after intravascular angiography: a systematic reveiw and meta-analysis. BMC Medicine 2004 2, article 38 2-s2.0-13844272133 10.1186/1741-7015-2-38 (Pubitemid 40251694)
55. Pannu N., Manns B., Lee H., Tonelli M., Systematic review of the impact of N-acetylcysteine on contrast nephropathy. Kidney International 2004 65 4 1366 1374 2-s2.0-1642545171 10.1111/j.1523-1755.2004.00516.x (Pubitemid 38406975)
56. Duong M. H., MacKenzie T. A., Malenka D. J., N-acetylcysteine prophylaxis significantly reduces the risk of radiocontrast-induced nephropathy: comprehensive meta-analysis. Catheterization and Cardiovascular Interventions 2005 64 4 471 479 2-s2.0-16244412258 10.1002/ccd.20342 (Pubitemid 40463445)
57. Liu R., Nair D., Ix J., Moore D. H., Bent S., N-acetylcysteine for the prevention of contrast-induced nephropathy: a systematic review and meta-analysis. Journal of General Internal Medicine 2005 20 2 193 200 2-s2.0-18244395035 10.1111/j.1525-1497.2005.30323.x (Pubitemid 40626999)
58. Kelly A. M., Dwamena B., Cronin P., Bernstein S. J., Carlos R. C., Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy. Annals of Internal Medicine 2008 148 4 284 294 2-s2.0-40049091486 (Pubitemid 351665489)
59. Kwok C. S., Pang C. L., Yeong J. K., Loke Y. K., Measures used to treat contrast-induced nephropathy: overview of reviews. British Journal of Radiology 2013 86 1021 20120272
60. Kshirsagar A. V., Poole C., Mottl A., Shoham D., Franceschini N., Tudor G., Agrawal M., Denu-Ciocca C., Ohman E. M., Finn W. F., N-acetylcysteine for the prevention of radiocontrast induced nephropathy: a meta-analysis of prospective controlled trials. Journal of the American Society of Nephrology 2004 15 3 761 769 2-s2.0-10744229574 10.1097/01.ASN.0000116241.47678.49 (Pubitemid 38294807)
61. Misra D., Leibowtiz K., Gowda R. M., Shapiro M., Khan I. A., Role of N-acetylcysteine in prevention of contrast-induced nephropathy after cardiovascular procedures: a meta-analysis. Clinical Cardiology 2004 27 11 607 610 2-s2.0-7444227936 (Pubitemid 39441741)
62. Nallamothu B. K., Shojania K. G., Saint S., Hofer T. P., Humes H. D., Moscucci M., Bates E. R., Is acetylcysteine effective in preventing contrast-related nephropathy? A meta-analysis. The American Journal of Medicine 2004 117 12 938 947 2-s2.0-11344275793 10.1016/j.amjmed.2004.06.046 (Pubitemid 40075562)
63. Zagler A., Azadpour M., Mercado C., Hennekens C. H., N-acetylcysteine and contrast-induced nephropathy: a meta-analysis of 13 randomized trials. The American Heart Journal 2006 151 1 140 145 2-s2.0-29144523846 10.1016/j.ahj.2005.01.055 (Pubitemid 41815344)
64. Gonzales D. A., Norsworthy K. J., Kern S. J., Banks S., Sieving P. C., Star R. A., Natanson C., Danner R. L., A meta-analysis of N-acetylcysteine in contrast-induced nephrotoxicity: unsupervised clustering to resolve heterogeneity. BMC Medicine 2007 5, article 32 2-s2.0-38349106545 10.1186/1741-7015-5-32
65. Sun Z., Fu Q., Cao L., Jin W., Cheng L., Li Z., Intravenous N-acetylcysteine for prevention of contrast-induced nephropathy: a meta-analysis of randomized, controlled trials. PLoS ONE 2013 8 1 e55124
66. Grosser N., Hemmerle A., Berndt G., Erdmann K., Hinkelmann U., Schürgerc S., Wijayanti N., Immenschuh S., Schröder H., The antioxidant defense protein heme oxygenase 1 is a novel target for statins in endothelial cells. Free Radical Biology and Medicine 2004 37 12 2064 2071 2-s2.0-8544284074 10.1016/j.freeradbiomed.2004.09.009 (Pubitemid 39491325)
67. Stoll L. L., McCormick M. L., Denning G. M., Weintraub N. L., Antioxidant effects of statins. Drugs of Today 2004 40 12 975 990 2-s2.0-12344280212 10.1358/dot.2004.40.12.872573 (Pubitemid 40128717)
68. Park J.-K., Muller D. N., Mervaala E. M. A., Dechend R., Fiebeler A., Schmidt F., Bieringer M., Schafer O., Lindschau C., Schneider W., Ganten D., Luft F. C., Haller H., Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects. Kidney International 2000 58 4 1420 1430 2-s2.0-0033802611 10.1046/j.1523-1755.2000. 00304.x
69. Gueler F., Rong S., Park J.-K., Fiebeler A., Menne J., Elger M., Mueller D. N., Hampich F., Dechend R., Kunter U., Luft F. C., Haller H., Postischemic acute renal failure is reduced by short-term statin treatment in a rat model. Journal of the American Society of Nephrology 2002 13 9 2288 2298 2-s2.0-0036707882 10.1097/01.ASN.0000026609.45827.3D (Pubitemid 34925239)
70. Mangano C. M., Diamondstone L. S., Ramsay J. G., Aggarwal A., Herskowitz A., Mangano D. T., Renal dysfunction after myocardial revascularization: risk factors, adverse outcomes, and hospital resource utilization. Annals of Internal Medicine 1998 128 3 194 203 2-s2.0-0032006881 (Pubitemid 28078200)
71. Attallah N., Yassine L., Musial J., Yee J., Fisher K., The potential role of statins in contrast nephropathy. Clinical Nephrology 2004 62 4 273 278 2-s2.0-6344228444 (Pubitemid 39386803)
72. Khanal S., Attallah N., Smith D. E., Kline-Rogers E., Share D., O'Donnell M. J., Moscucci M., Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. The American Journal of Medicine 2005 118 8 843 849 2-s2.0-23244448755 10.1016/j.amjmed.2005.03.031 (Pubitemid 41097461)
73. Xinwei J., Xianghua F., Jing Z., Xinshun G., Ling X., Weize F., Guozhen H., Yunfa J., Weili W., Shiqiang L., Comparison of usefulness of simvastatin 20 mg versus 80 mg in preventing contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. The American Journal of Cardiology 2009 104 4 519 524 2-s2.0-67849122782 10.1016/j.amjcard.2009.04.014
74. Jo S.-H., Koo B.-K., Park J.-S., Kang H.-J., Cho Y.-S., Kim Y.-J., Youn T.-J., Chung W.-Y., Chae I.-H., Choi D.-J., Sohn D.-W., Oh B.-H., Park Y.-B., Choi Y.-S., Kim H.-S., Prevention of radiocontrast medium-induced nephropathy using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angiography (PROMISS) trial-a randomized controlled study. The American Heart Journal 2008 155 3 499 e1 2-s2.0-39249083997 10.1016/j.ahj.2007.11.042
75. Özhan H., Erden I., Ordu S., Aydin M., Caglar O., Basar C., Yalcin S., Alemdar R., Efficacy of short-term high-dose atorvastatin for prevention of contrast-induced nephropathy in patients undergoing coronary angiography. Angiology 2010 61 7 711 714 2-s2.0-77956467157 10.1177/0003319710364216
76. Toso A., Maioli M., Leoncini M., Gallopin M., Tedeschi D., Micheletti C., Manzone C., Amato M., Bellandi F., Usefulness of Atorvastatin (80 mg) in Prevention of Contrast-Induced Nephropathy in Patients With Chronic Renal Disease. The American Journal of Cardiology 2010 105 3 288 292 2-s2.0-74049158672 10.1016/j.amjcard.2009.09.026
77. Patti G., Ricottini E., Nusca A., Colonna G., Pasceri V., D'Ambrosio A., Montinaro A., Di Sciascio G., Short-term, high-dose atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty-contrast-induced nephropathy] trial. The American Journal of Cardiology 2011 108 1 1 7 2-s2.0-79958816893 10.1016/j.amjcard.2011.03.001
78. Quintavalle C., Fiore D., de Micco F., Visconti G., Focaccio A., Golia B., Ricciardelli B., Donnarumma E., Bianco A., Zabatta M. A., Troncone G., Colombo A., Briguori C., Condorelli G., Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury. Circulation 2012 126 25 3008 3016
79. Han Y., Zhu G., Han L., Hou F., Huang W., Liu H., Gan J., Jiang T., Li X., Wang W., Ding S., Jia S., Shen W., Wang D., Sun L., Qiu J., Wang X., Li Y., Deng J., Li J., Xu K., Xu B., Mehran R., Huo Y., Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease. Journal of the American College of Cardiology 2014 63 1 62 70 10.1016/j.jacc.2013.09.017
80. Leoncini M., Toso A., Maioli M., Tropeano F., Villani S., Bellandi F., Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome. Results from protective effect of rosuvastatin and antiplatelet therapy on contrast-induced acute kidney injury and myocardial damage in patients with acute coronary syndrome (PRATO-ACS study). Journal of the American College of Cardiology 2014 63 1 71 79 10.1016/j.jacc.2013.04.105
81. Zhang B.-C., Li W.-M., Xu Y.-W., High-dose statin pretreatment for the prevention of contrast-induced nephropathy: a meta-analysis. Canadian Journal of Cardiology 2011 27 6 851 858 2-s2.0-82155185146 10.1016/j.cjca.2011.05.005
82. Zhou Y., Yuan W. J., Zhu N., Wang L., Short-term, high-dose statins in the prevention of contrast-induced nephropathy: a systematic review and meta-analysis. Clinical Nephrology 2011 76 6 475 483 2-s2.0-84855432039 10.5414/CN106950
83. Zhang T., Shen L.-H., Hu L.-H., He B., Statins for the prevention of contrast-induced nephropathy: a systematic review and meta-analysis. The American Journal of Nephrology 2011 33 4 344 351 2-s2.0-79952820559 10.1159/000326269
84. Durak I., Özbek H., Karaayvaz M., Öztürk H. S., Cisplatin induces acute renal failure by impairing antioxidant system in guinea pigs: effects of antioxidant supplementation on the cisplatin nephrotoxicity. Drug and Chemical Toxicology 2002 25 1 1 8 2-s2.0-0036166246 10.1081/DCT-100108468 (Pubitemid 34132348)
85. Lloberas N., Torras J., Herrero-Fresneda I., Cruzado J. M., Riera M., Hurtado I., Grinyó J. M., Postischemic renal oxidative stress induces inflammatory response through PAF and oxidized phospholipids. Prevention by antioxidant treatment. The FASEB Journal 2002 16 8 908 910 2-s2.0-0036616873
86. Ali B. H., Agents ameliorating or augmenting experimental gentamicin nephrotoxicity: some recent research. Food and Chemical Toxicology 2003 41 11 1447 1452 2-s2.0-0041880000 10.1016/S0278-6915(03)00186-8 (Pubitemid 37088099)
87. McCullough P. A., Wolyn R., Rocher L. L., Levin R. N., O'Neill W. W., Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. The American Journal of Medicine 1997 103 5 368 375 2-s2.0-0030661687 10.1016/S0002-9343(97)00150-2 (Pubitemid 27506242)
88. Spargias K., Alexopoulos E., Kyrzopoulos S., Iacovis P., Greenwood D. C., Manginas A., Voudris V., Pavlides G., Buller C. E., Kremastinos D., Cokkinos D. V., Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation 2004 110 18 2837 2842 2-s2.0-8144224968 10.1161/01.CIR.0000146396.19081.73 (Pubitemid 39473606)
89. Boscheri A., Weinbrenner C., Botzek B., Reynen K., Kuhlisch E., Strasser R. H., Failure of ascorbic acid to prevent contrast-media induced nephropathy in patients with renal dysfunction. Clinical Nephrology 2007 68 5 279 286 2-s2.0-35748975978 (Pubitemid 350047760)
90. Jo S.-H., Koo B.-K., Park J.-S., Kang H.-J., Kim Y.-J., Kim H.-L., Chae I.-H., Choi D.-J., Sohn D.-W., Oh B.-H., Park Y.-B., Choi Y.-S., Kim H.-S., N-acetylcysteine versus AScorbic acid for preventing contrast-induced nephropathy in patients with renal insufficiency undergoing coronary angiography. NASPI study-a prospective randomized controlled trial. The American Heart Journal 2009 157 3 576 583 2-s2.0-60949106571 10.1016/j.ahj.2008.11.010
91. Zhou L., Chen H., Prevention of contrast-induced nephropathy with ascorbic acid. Internal Medicine 2012 51 6 531 535 2-s2.0-84858185220 10.2169/internalmedicine.51.6260
92. Brueck M., Cengiz H., Hoeltgen R., Wieczorek M., Boedeker R. H., Scheibelhut C., Boening A., Usefulness of N-acetylcysteine or ascorbic acid versus placebo to prevent contrast-induced acute kidney injury in patients undergoing elective cardiac catheterization: a single-center, prospective, randomized, double-blind, placebo-controlled trial. Journal of Invasive Cardiology 2013 25 6 276 283
93. Tasanarong A., Piyayotai D., Thitiarchakul S., Protection of radiocontrast induced nephropathy by vitamin E (alpha tocopherol): a randomized controlled pilot study. Journal of the Medical Association of Thailand 2009 92 10 1273 1281 2-s2.0-70449120459
94. Tasanarong A., Vohakiat A., Hutayanon P., Piyayotai D., New strategy of alpha- and gamma-tocopherol to prevent contrast-induced acute kidney injury in chronic kidney disease patients undergoing elective coronary procedures. Nephrology Dialysis Transplantation 2013 28 2 337 344
95. Kitzler T. M., Jaberi A., Sendlhofer G., Rehak P., Binder C., Petnehazy E., Stacher R., Kotanko P., Efficacy of vitamin E and N-acetylcysteine in the prevention of contrast induced kidney injury in patients with chronic kidney disease: a double blind, randomized controlled trial. Wiener Klinische Wochenschrift 2012 124 9-10 312 319 2-s2.0-84859912931 10.1007/s00508-012-0169-2
96. Workman R. J., Shaff M. I., Jackson R. V., Diggs J., Frazer M. G., Briscoe C., Relationship of renal hemodynamic and functional changes following intravascular contrast to the renin-angiotensin system and renal prostacyclin in the dog. Investigative Radiology 1983 18 2 160 166 2-s2.0-0020574690 (Pubitemid 13111339)
97. Heyman S. N., Brezis M., Epstein F. H., Spokes K., Silva P., Rosen S., Early renal medullary hypoxic injury from radiocontrast and indomethacin. Kidney International 1991 40 4 632 642 2-s2.0-0026094370
98. Elkayam U., Ng T. M. H., Hatamizadeh P., Janmohamed M., Mehra A., Renal vasodilatory action of dopamine in patients with heart failure: magnitude of effect and site of action. Circulation 2008 117 2 200 205 2-s2.0-38049160214 10.1161/CIRCULATIONAHA.107.737106
99. Kapoor A., Sinha N., Sharma R. K., Shrivastava S., Radhakrishnan S., Goel P. K., Bajaj R., Use of dopamine in prevention of contrast induced acute renal failure-a randomised study. International Journal of Cardiology 1996 53 3 233 236 2-s2.0-0030007676 10.1016/0167-5273(95)02547-2 (Pubitemid 26178156)
100. Hans S. S., Hans B. A., Dhillon R., Dmuchowski C., Glover J., Effect of dopamine on renal function after arteriography in patients with pre-existing renal insufficiency. The American Surgeon 1998 64 5 432 436 2-s2.0-0031979049 (Pubitemid 28208787)
101. Abizaid A. S., Clark C. E., Mintz G. S., Dosa S., Popma J. J., Pichard A. D., Satler L. F., Harvey M., Kent K. M., Leon M. B., Effects of dopamine and aminophylline on contrast-induced acute renal failure after coronary angioplasty in patients with preexisting renal insufficiency. The American Journal of Cardiology 1999 83 2 260 263 2-s2.0-0033556380 10.1016/S0002-9149(98)00833-9 (Pubitemid 29047309)
102. Stevens M. A., McCullough P. A., Tobin K. J., Speck J. P., Westveer D. C., Guido-Allen D. A., Timmis G. C., O'Neill W. W., A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. study. Prevention of radiocontrast induced nephropathy clinical evaluation. Journal of the American College of Cardiology 1999 33 2 403 411 2-s2.0-0033081743 10.1016/S0735-1097(98)00574-9 (Pubitemid 29234202)
103. Allaqaband S., Tumuluri R., Malik A. M., Gupta A., Volkert P., Shalev Y., Bajwa T. K., Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. Catheterization and Cardiovascular Interventions 2002 57 3 279 283 2-s2.0-0036843034 10.1002/ccd.10323 (Pubitemid 35266257)
104. Stone G. W., McCullough P. A., Tumlin J. A., Lepor N. E., Madyoon H., Murray P., Wang A., Alan Chu A., Schaer G. L., Stevens M., Wilensky R. L., O'Neill W. W., Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. Journal of the American Medical Association 2003 290 17 2284 2291 2-s2.0-0242493661 10.1001/jama.290.17.2284 (Pubitemid 37430561)
105. Ng T. M. H., Shurmur S. W., Silver M., Nissen L. R., O'Leary E. L., Rigmaiden R. S., Cieciorka M., Porter L. L., Ineck B. A., Kline M. E., Puumala S. E., Comparison of N-acetylcysteine and fenoldopam for preventing contrast-induced nephropathy (CAFCIN). International Journal of Cardiology 2006 109 3 322 328 2-s2.0-33646468350 10.1016/j.ijcard.2005.06.038
106. Arend L. J., Bakris G. L., Burnett J. C. Jr., Megerian C., Spielman W. S., Role for intrarenal adenosine in the renal hemodynamic response to contrast media. Journal of Laboratory and Clinical Medicine 1987 110 4 406 411 2-s2.0-0023576910 (Pubitemid 18029904)
107. Huber W., Ilgmann K., Page M., Hennig M., Schweigart U., Jeschke B., Lutilsky L., Weiss W., Salmhofer H., Classen M., Effect of theophylline on contrast material-induced nephropathy in patients with chronic renal insufficiency: controlled, randomized, double-blinded study. Radiology 2002 223 3 772 779 2-s2.0-0036107523 (Pubitemid 34547597)
108. Huber W., Schipek C., Ilgmann K., Page M., Hennig M., Wacker A., Schweigart U., Lutilsky L., Valina C., Seyfarth M., Schömig A., Classen M., Effectiveness of theophylline prophylaxis of renal impairment after coronary angiography in patients with chronic renal insufficiency. The American Journal of Cardiology 2003 91 10 1157 1162 2-s2.0-0038402529 10.1016/S0002-9149(03) 00259-5 (Pubitemid 36561376)
109. Huber W., Eckel F., Hennig M., Rosenbrock H., Wacker A., Saur D., Sennefelder A., Hennico R., Schenk C., Meining A., Schmelz R., Fritsch R., Weiss W., Hamar P., Heemann U., Schmid R. M., Prophylaxis of contrast material-induced nephropathy in patients in intensive care: acetylcysteine, theophylline, or both? A randomized study. Radiology 2006 239 3 793 804 2-s2.0-33744811961 10.1148/radiol.2393041456 (Pubitemid 43830615)
110. Baskurt M., Okcun B., Abaci O., Dogan G. M., Kilickesmez K., Ozkan A. A., Ersanli M., Gurmen T., N-acetylcysteine versus N-acetylcysteine + theophylline for the prevention of contrast nephropathy. European Journal of Clinical Investigation 2009 39 9 793 799 2-s2.0-68349139193 10.1111/j.1365-2362.2009. 02173.x
111. Kinbara T., Hayano T., Ohtani N., Furutani Y., Moritani K., Matsuzaki M., Efficacy of N-acetylcysteine and aminophylline in preventing contrast-induced nephropathy. Journal of Cardiology 2010 55 2 174 179 2-s2.0-77349118433 10.1016/j.jjcc.2009.10.006
112. Bilasy M. E., Oraby M. A., Ismail H. M., Maklady F. A., Effectiveness of theophylline in preventing contrast-induced nephropathy after coronary angiographic procedures. Journal of Interventional Cardiology 2012 25 4 404 410
113. Ix J. H., McCulloch C. E., Chertow G. M., Theophylline for the prevention
114. Dai B., Liu Y., Fu L., Li Y., Zhang J., Mei C., Effect of theophylline on prevention of contrast-induced acute kidney injury: a meta-analysis of randomized controlled trials. The American Journal of Kidney Diseases 2012 60 3 360 370 2-s2.0-84859709851 10.1053/j.ajkd.2012.02.332
115. Bagshaw S. M., Ghali W. A., Theophylline for prevention of contrast-induced nephropathy: a systematic review and meta-analysis. Archives of Internal Medicine 2005 165 10 1087 1093 2-s2.0-19344368921 10.1001/archinte. 165.10.1087 (Pubitemid 40720732)
116. Sule S. S., Frishman W., Nebivolol: new therapy update. Cardiology in Review 2006 14 5 259 264 2-s2.0-33748053993 10.1097/01.crd.0000223651.03023.8e (Pubitemid 44298023)
117. Veverka A., Nuzum D. S., Jolly J. L., Nebivolol: a third-generation β -adrenergic blocker. Annals of Pharmacotherapy 2006 40 7-8 1353 1360 2-s2.0-33746990729 10.1345/aph.1G708 (Pubitemid 44204966)
118. Toprak O., Cirit M., Tanrisev M., Yazici C., Canoz O., Sipahioglu M., Uzum A., Ersoy R., Sozmen E. Y., Preventive effect of nebivolol on contrast-induced nephropathy in rats. Nephrology Dialysis Transplantation 2008 23 3 853 859 2-s2.0-42449136651 10.1093/ndt/gfm691 (Pubitemid 351767560)
119. Avci E., Yeşil M., Bayata S., Postaci N., Arikan E., Cirit M., The role of nebivolol in the prevention of contrast-induced nephropathy in patients with renal dysfunction. Anadolu Kardiyoloji Dergisi 2011 11 7 613 617 2-s2.0-80054694709 10.5152/akd.2011.164
120. Günebakmaz Ö., Kaya M. G., Koc F., Akpek M., Kasapkara A., Inanc M. T., Yarlioglues M., Calapkorur B., Karadag Z., Oguzhan A., Does nebivolol prevent contrast-induced nephropathy in humans? Clinical Cardiology 2012 35 4 250 254 2-s2.0-84859775816 10.1002/clc.21013
121. Huang C.-L., Lewicki J., Johnson L. K., Cogan M. G., Renal mechanism of action of rat atrial natriuretic factor. Journal of Clinical Investigation 1985 75 2 769 773 2-s2.0-0021953885 (Pubitemid 15142092)
122. Nakamoto M., Shapiro J. I., Shanley P. F., Chan L., Schrier R. W., In vitro and in vivo protective effect of atriopeptin III on ischemic acute renal failure. Journal of Clinical Investigation 1987 80 3 698 705 2-s2.0-0023514949 (Pubitemid 18003940)
123. Margulies K. B., McKinley L. J., Cavero P. G., Burnett J. C. Jr., Induction and prevention of radiocontrast-induced nephropathy in dogs with heart failure. Kidney International 1990 38 6 1101 1108 2-s2.0-0025251150
124. Kurnik B. R. C., Allgren R. L., Center F. C., Solomon R. J., Bates E. R., Weisberg L. S., Prospective study of atrial natriuretic peptide for the prevention of radiocontrast-induced nephropathy. The American Journal of Kidney Diseases 1998 31 4 674 680 2-s2.0-0031897391 (Pubitemid 28158009)
125. Morikawa S., Sone T., Tsuboi H., Mukawa H., Morishima I., Uesugi M., Morita Y., Numaguchi Y., Okumura K., Murohara T., Renal protective effects and the prevention of contrast-induced nephropathy by atrial natriuretic peptide. Journal of the American College of Cardiology 2009 53 12 1040 1046 2-s2.0-61949457295 10.1016/j.jacc.2008.10.061
126. Harris R. C., Physiologic and pathophysiologic roles of cyclooxygenase-2 in the kidney. Transactions of the American Clinical and Climatological Association 2013 124 139 151
127. Schlondorff D., Renal prostaglandin synthesis. Sites of production and specific actions of prostaglandins. The American Journal of Medicine 1986 81 2B 1 11 2-s2.0-0022502884 10.1016/0002-9343(86)90903-4 (Pubitemid 16006978)
128. Krause W., Muschick P., Krüger U., Use of near-infrared reflection spectroscopy to study the effects of x-ray contrast media on renal tolerance in rats: effects of a prostacyclin analogue and of phosphodiesterase inhibitors. Investigative Radiology 2002 37 12 698 705 2-s2.0-0036896858 10.1097/00004424-200212000-00010 (Pubitemid 35429191)
129. Paller M. S., Manivel J. C., Prostaglandins protect kidneys against ischemic and toxic injury by a cellular effect. Kidney International 1992 42 6 1345 1354 2-s2.0-0026446555
130. Grekas D., Kalekou H., Tourkantonis A., Effect of prostaglandin E2 (PGE2) in the prevention of acute renal failure in anesthetized dogs. In situ renal preservation. Renal Failure 1989 11 1 27 31 2-s2.0-0024473659 (Pubitemid 19200198)
131. Gurkowski L., MacDougall M., Wiegmann T., Effects of misoprostol on contrast-induced renal dysfunction. The American Journal of Therapeutics 1995 2 11 837 842
132. Spargias K., Adreanides E., Demerouti E., Gkouziouta A., Manginas A., Pavlides G., Voudris V., Cokkinos D. V., Iloprost prevents contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation 2009 120 18 1793 1799 2-s2.0-70449449081 10.1161/CIRCULATIONAHA.109.863159
133. Boccalandro F., Amhad M., Smalling R. W., Sdringola S., Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast. Catheterization and Cardiovascular Interventions 2003 58 3 336 341 2-s2.0-0037371588 10.1002/ccd.10389 (Pubitemid 36259222)
134. Gomes V. O., Poli de Figueredo C. E., Caramori P., Lasevitch R., Bodanese L. C., Araújo A., Röedel A. P., Caramori A. P., Brito F. S. Jr., Bezerra H. G., Nery P., Brizolara A., N-acetylcysteine does not prevent contrast induced nephropathy after cardiac catheterisation with an ionic low osmolality contrast medium: a multicentre clinical trial. Heart 2005 91 6 774 778 2-s2.0-20044396242 10.1136/hrt.2004.039636 (Pubitemid 40769223)
135. Ozcan E. E., Guneri S., Akdeniz B., Akyildiz I. Z., Senaslan O., Baris N., Aslan O., Badak O., Sodium bicarbonate, N-acetylcysteine, and saline for prevention of radiocontrast-induced nephropathy. A comparison of 3 regimens for protecting contrast-induced nephropathy in patients undergoing coronary procedures. A single-center prospective controlled trial. The American Heart Journal 2007 154 3 539 544 2-s2.0-34547944556 10.1016/j.ahj.2007.05.012 (Pubitemid 47268251)